Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant plus Ribociclib in 1st Line ER+ HER2- Advanced Breast Cancer
NCT07647328Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Primary completion
- Feb 2029
- Countries
- 9
01
Overview
A Phase 3 trial of camizestrant in breast cancer, sponsored by AstraZeneca. Started Jun 2026; status: recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07647328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647328.